
A scannable review of Oct. 12–16: Penske Automotive's $16.3 billion take-private, Bank of America's $1.21 billion money-laundering penalty, two biotech IPOs that beat a falling market, hot CPI and PPI readings that briefly put an October hike back in play, JPMorgan's rare miss against Goldman's blowout quarter, and the week AI-linked credit was repriced.
| Issuer | Deal size | Market cap at IPO | Price vs. midpoint | First day | Return at 10/16 |
|---|---|---|---|---|---|
City Therapeutics CTY 7 | $200M | $1,027M | 0% | +24% | +24% |
Iambic Therapeutics IAM 7 | $150M | $809M | 0% | +18% | +49% |
TCGX Acquisition II TCXB 7 | $100M | $130M | 0% | +9% | +9% |
Amaero AMRO 7 | $20M | $121M | −40% | +4% | +6% |
Frazier Life Sciences II FLSC 7 | $75M | $97M | 0% | +3% | +4% |
reuters.com
investopedia.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
investors.penskeautomotive.com
terrainlabs.ai
proofpoint.com
reuters.com
terrainlabs.ai
reuters.com
terrainlabs.ai
terrainlabs.ai
home.treasury.gov
occ.gov
sec.gov
reuters.com
jpmorganchase.com
goldmansachs.com
reuters.com
morganstanley.com
investor.tsmc.com
reuters.com
terrainlabs.ai
terrainlabs.ai
terrainlabs.ai
terrainlabs.ai
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.